voriconazole Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
systemic antifungal agents, miconazole derivatives 2846 137234-62-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • voriconazole
  • voriconazol
  • vfend
  • UK109496
  • UK-109496
  • UK 109496
A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.
  • Molecular weight: 349.32
  • Formula: C16H14F3N5O
  • CLOGP: 0.52
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 1
  • TPSA: 76.72
  • ALOGS: -3.55
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O
0.40 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.39 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 34.35 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 96 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.42 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
May 24, 2002 FDA PF PRISM CV

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bronchopulmonary aspergillosis 646.10 15.75 203 19487 7293 46659079
Aspergillus infection 521.28 15.75 169 19521 6721 46659651
Drug interaction 329.88 15.75 416 19274 202678 46463694
Mucormycosis 283.27 15.75 82 19608 2210 46664162
Periostitis 280.11 15.75 53 19637 182 46666190
Multiple organ dysfunction syndrome 197.35 15.75 168 19522 51542 46614830
Drug level increased 186.81 15.75 109 19581 18332 46648040
Drug resistance 184.82 15.75 106 19584 17262 46649110
Photosensitivity reaction 183.10 15.75 95 19595 12697 46653675
Septic shock 165.67 15.75 160 19530 57733 46608639
Pneumonia fungal 164.45 15.75 63 19627 4097 46662275
Febrile neutropenia 150.11 15.75 192 19498 94435 46571937
Drug level below therapeutic 143.98 15.75 53 19637 3084 46663288
Fungal infection 135.85 15.75 107 19583 29413 46636959
Drug level decreased 123.95 15.75 57 19633 5855 46660517
Respiratory failure 122.31 15.75 174 19516 94642 46571730
Cerebral aspergillosis 118.72 15.75 28 19662 326 46666046
Acute myeloid leukaemia 118.32 15.75 77 19613 15701 46650671
Graft versus host disease 118.06 15.75 57 19633 6531 46659841
Cholestasis 107.92 15.75 90 19600 26803 46639569
Dilatation intrahepatic duct acquired 106.67 15.75 30 19660 726 46665646
Fatigue 104.77 15.75 64 19626 608633 46057739
Scedosporium infection 102.88 15.75 27 19663 499 46665873
Systemic mycosis 96.24 15.75 29 19661 900 46665472
Hallucination, visual 93.64 15.75 70 19620 17803 46648569
Actinic keratosis 85.25 15.75 33 19657 2206 46664166
Pathogen resistance 83.82 15.75 44 19646 6016 46660356
Pancytopenia 82.71 15.75 137 19553 84921 46581451
Fusarium infection 81.84 15.75 23 19667 555 46665817
Visual impairment 80.98 15.75 119 19571 66570 46599802
Hallucination 80.12 15.75 102 19588 49849 46616523
Pain 79.38 15.75 52 19638 476896 46189476
Venoocclusive liver disease 76.83 15.75 37 19653 4214 46662158
Fluoride increased 71.54 15.75 12 19678 15 46666357
Hepatotoxicity 71.23 15.75 69 19621 24940 46641432
Photodermatosis 71.08 15.75 19 19671 378 46665994
Drug ineffective 70.04 15.75 506 19184 677332 45989040
Geotrichum infection 67.82 15.75 19 19671 453 46665919
Blood bilirubin increased 66.52 15.75 77 19613 34107 46632265
Pyrexia 65.14 15.75 305 19385 348497 46317875
Sepsis 62.79 15.75 161 19529 135853 46530519
Acute graft versus host disease in intestine 61.06 15.75 24 19666 1671 46664701
Hypertrophic osteoarthropathy 60.30 15.75 11 19679 29 46666343
Squamous cell carcinoma of skin 59.00 15.75 33 19657 5114 46661258
Pneumonia 53.49 15.75 305 19385 376015 46290357
Keratitis fungal 53.19 15.75 12 19678 113 46666259
Neurotoxicity 53.14 15.75 45 19645 13672 46652700
Fall 51.83 15.75 38 19652 329059 46337313
Graft versus host disease in gastrointestinal tract 51.62 15.75 24 19666 2526 46663846
Fungaemia 50.70 15.75 22 19668 1969 46664403
Acute graft versus host disease in liver 49.59 15.75 16 19674 624 46665748
Cytomegalovirus viraemia 49.40 15.75 28 19662 4450 46661922
Acute graft versus host disease 49.38 15.75 27 19663 4003 46662369
Immunosuppressant drug level increased 48.74 15.75 25 19665 3257 46663115
Hepatic function abnormal 48.53 15.75 66 19624 34355 46632017
Blood alkaline phosphatase increased 48.51 15.75 71 19619 39538 46626834
Acute graft versus host disease in skin 48.04 15.75 24 19666 2958 46663414
Acute myeloid leukaemia recurrent 47.61 15.75 19 19671 1377 46664995
Fungal test positive 47.56 15.75 15 19675 543 46665829
Product use in unapproved indication 47.06 15.75 112 19578 90161 46576211
Cytomegalovirus infection 46.00 15.75 47 19643 18097 46648275
Gamma-glutamyltransferase increased 44.96 15.75 61 19629 31679 46634693
Headache 44.50 15.75 84 19606 478268 46188104
Squamous cell carcinoma 43.98 15.75 32 19658 7804 46658568
Strongyloidiasis 41.12 15.75 15 19675 850 46665522
Graft versus host disease in skin 40.96 15.75 20 19670 2347 46664025
Acute respiratory distress syndrome 40.34 15.75 48 19642 21874 46644498
Drug hypersensitivity 39.87 15.75 27 19663 243798 46422574
Fluorosis 39.39 15.75 7 19683 15 46666357
Chronic graft versus host disease 38.29 15.75 20 19670 2705 46663667
Product dose omission issue 37.82 15.75 12 19678 168508 46497864
Joint swelling 36.96 15.75 12 19678 166061 46500311
Corneal perforation 36.57 15.75 12 19678 494 46665878
Liver function test abnormal 36.24 15.75 68 19622 46419 46619953
Phaeohyphomycosis 35.95 15.75 10 19680 232 46666140
Thrombotic microangiopathy 35.82 15.75 29 19661 8277 46658095
Halo vision 35.80 15.75 11 19679 365 46666007
Lentigo 35.40 15.75 10 19680 246 46666126
Lung transplant rejection 35.31 15.75 13 19677 756 46665616
Arthralgia 34.77 15.75 63 19627 364540 46301832
Pain in extremity 34.45 15.75 35 19655 258645 46407727
Posterior reversible encephalopathy syndrome 34.41 15.75 37 19653 15104 46651268
Dizziness 34.11 15.75 57 19633 340357 46326015
Pseudomonas infection 33.73 15.75 30 19660 9728 46656644
Hypertransaminasaemia 33.68 15.75 20 19670 3468 46662904
Cerebral fungal infection 33.66 15.75 7 19683 43 46666329
Dyschromatopsia 33.60 15.75 10 19680 297 46666075
Neutropenia 32.52 15.75 133 19557 143071 46523301
Adenovirus infection 32.04 15.75 18 19672 2812 46663560
Lower respiratory tract infection fungal 31.42 15.75 9 19681 233 46666139
Brain abscess 31.21 15.75 15 19675 1700 46664672
Aspergillus test 30.92 15.75 5 19685 4 46666368
Pruritus 30.91 15.75 34 19656 242318 46424054
Granulomatous liver disease 30.83 15.75 12 19678 814 46665558
Hepatocellular injury 30.62 15.75 49 19641 29473 46636899
Musculoskeletal stiffness 30.50 15.75 3 19687 97990 46568382
Pulmonary alveolar haemorrhage 30.43 15.75 20 19670 4142 46662230
Platelet count decreased 30.33 15.75 102 19588 99922 46566450
Altered state of consciousness 30.26 15.75 43 19647 23305 46643067
Solar lentigo 30.16 15.75 11 19679 623 46665749
Infective aneurysm 30.10 15.75 10 19680 428 46665944
Systemic candida 29.94 15.75 17 19673 2710 46663662
Exposure during pregnancy 29.62 15.75 5 19685 108207 46558165
Pneumonia bacterial 29.62 15.75 24 19666 6855 46659517
Immunosuppressant drug level decreased 29.42 15.75 12 19678 920 46665452
Enterococcal infection 29.29 15.75 24 19666 6963 46659409
Bone marrow failure 29.08 15.75 48 19642 29621 46636751
Chromatopsia 28.86 15.75 10 19680 487 46665885
Aspergillus test positive 28.75 15.75 9 19681 318 46666054
Encephalopathy 28.53 15.75 51 19639 33538 46632834
Acute lymphocytic leukaemia recurrent 28.37 15.75 15 19675 2080 46664292
Nasopharyngitis 28.03 15.75 15 19675 153983 46512389
Diarrhoea 27.59 15.75 132 19558 559470 46106902
Alanine aminotransferase increased 27.53 15.75 91 19599 88360 46578012
Toxic epidermal necrolysis 27.36 15.75 40 19650 22238 46644134
Abdominal discomfort 27.11 15.75 15 19675 151150 46515222
Nausea 26.92 15.75 175 19515 687279 45979093
Trichosporon infection 26.77 15.75 8 19682 241 46666131
Coccidioidomycosis 26.62 15.75 11 19679 872 46665500
Haemoptysis 26.52 15.75 43 19647 26146 46640226
Venoocclusive disease 26.47 15.75 14 19676 1942 46664430
Fungal endocarditis 26.46 15.75 8 19682 251 46666121
Renal impairment 26.33 15.75 80 19610 74292 46592080
Aspartate aminotransferase increased 26.33 15.75 83 19607 78617 46587755
Delirium 26.01 15.75 52 19638 37176 46629196
Candida infection 25.98 15.75 39 19651 22201 46644171
Graft versus host disease in liver 25.77 15.75 9 19681 449 46665923
Primary myelofibrosis 25.75 15.75 6 19684 66 46666306
Colour blindness 25.71 15.75 8 19682 277 46666095
Leukaemia recurrent 25.50 15.75 12 19678 1297 46665075
Dermatitis bullous 25.43 15.75 23 19667 7620 46658752
Urticaria 25.38 15.75 9 19681 117883 46548489
Photophobia 25.37 15.75 31 19659 14513 46651859
Arthropathy 25.32 15.75 3 19687 84697 46581675
Cytokine release syndrome 25.31 15.75 21 19669 6202 46660170
Obliterative bronchiolitis 24.86 15.75 13 19677 1762 46664610
Urinary tract infection 24.81 15.75 34 19656 220232 46446140
Disseminated intravascular coagulation 24.62 15.75 35 19655 18970 46647402
Leukaemia 24.49 15.75 16 19674 3279 46663093
Graft versus host disease in lung 24.46 15.75 8 19682 326 46666046
Malaise 24.35 15.75 66 19624 331166 46335206
Leukoencephalopathy 23.95 15.75 17 19673 3987 46662385
Peripheral swelling 23.88 15.75 19 19671 158052 46508320
Infective pulmonary exacerbation of cystic fibrosis 23.84 15.75 26 19664 10781 46655591
Anxiety 23.77 15.75 25 19665 181932 46484440
Pseudoaldosteronism 23.73 15.75 5 19685 33 46666339
Pneumothorax 23.63 15.75 30 19660 14599 46651773
Myocardial infarction 23.61 15.75 6 19684 97522 46568850
Maternal exposure during pregnancy 23.54 15.75 7 19683 102542 46563830
Disease progression 23.30 15.75 88 19602 91212 46575160
Chronic graft versus host disease in skin 23.08 15.75 9 19681 613 46665759
Stenotrophomonas infection 23.08 15.75 12 19678 1608 46664764
Asthenia 22.85 15.75 62 19628 311013 46355359
Swelling 22.84 15.75 12 19678 124499 46541873
Staphylococcal infection 22.67 15.75 48 19642 35723 46630649
Pulmonary haemorrhage 22.48 15.75 20 19670 6485 46659887
Procalcitonin increased 22.38 15.75 9 19681 665 46665707
Post transplant lymphoproliferative disorder 22.21 15.75 16 19674 3840 46662532
Therapeutic product effect decreased 22.20 15.75 4 19686 82597 46583775
Electrocardiogram QT prolonged 21.84 15.75 59 19631 51266 46615106
Thrombocytopenia 21.56 15.75 108 19582 126473 46539899
Depression 21.52 15.75 24 19666 170080 46496292
Bronchopulmonary aspergillosis allergic 21.50 15.75 9 19681 737 46665635
Disseminated cryptococcosis 21.38 15.75 7 19683 286 46666086
Tonsillitis bacterial 21.18 15.75 6 19684 149 46666223
Tracheobronchitis 21.07 15.75 10 19680 1102 46665270
Chronic papillomatous dermatitis 21.06 15.75 5 19685 60 46666312
Bacterial sepsis 21.00 15.75 15 19675 3552 46662820
Palpitations 20.97 15.75 7 19683 95252 46571120
Muscle spasms 20.96 15.75 13 19677 123100 46543272
Drug-induced liver injury 20.88 15.75 38 19652 25330 46641042
Scintillating scotoma 20.74 15.75 6 19684 161 46666211
Hepatic candidiasis 20.66 15.75 4 19686 16 46666356
Aspergilloma 20.43 15.75 6 19684 170 46666202
Liver disorder 20.24 15.75 47 19643 37199 46629173
Encephalitis 20.17 15.75 20 19670 7428 46658944
Renal failure 20.11 15.75 98 19592 113496 46552876
Abdominal pain upper 20.08 15.75 19 19671 145286 46521086
Rash 20.01 15.75 80 19610 356432 46309940
Septal panniculitis 19.97 15.75 5 19685 76 46666296
Tuberculosis gastrointestinal 19.93 15.75 7 19683 355 46666017
Torsade de pointes 19.75 15.75 25 19665 12129 46654243
Bacteraemia 19.69 15.75 27 19663 14152 46652220
Acute lymphocytic leukaemia 19.48 15.75 13 19677 2760 46663612
Blood pressure increased 19.41 15.75 15 19675 126651 46539721
Eye abscess 19.28 15.75 5 19685 88 46666284
Agranulocytosis 19.24 15.75 34 19656 22151 46644221
Hepatosplenic candidiasis 19.03 15.75 6 19684 217 46666155
Aplastic anaemia 18.99 15.75 19 19671 7134 46659238
Hallucination, auditory 18.88 15.75 23 19667 10733 46655639
Cystitis haemorrhagic 18.81 15.75 14 19676 3533 46662839
Pleural effusion 18.77 15.75 77 19613 82875 46583497
Dermatitis exfoliative 18.62 15.75 17 19673 5699 46660673
Fungal skin infection 18.62 15.75 14 19676 3588 46662784
Back pain 18.49 15.75 38 19652 210001 46456371
Bacterial infection 18.32 15.75 28 19662 16188 46650184
Drug clearance decreased 18.28 15.75 9 19681 1075 46665297
Cholecystitis acute 18.15 15.75 19 19671 7519 46658853
Acute kidney injury 18.08 15.75 165 19525 235690 46430682
Death 17.86 15.75 218 19472 335330 46331042
Osteomyelitis fungal 17.78 15.75 3 19687 4 46666368
Treatment failure 17.70 15.75 82 19608 93005 46573367
Infection reactivation 17.70 15.75 8 19682 789 46665583
Endophthalmitis 17.52 15.75 13 19677 3265 46663107
Laryngeal inflammation 17.47 15.75 5 19685 129 46666243
Skin cancer 17.36 15.75 20 19670 8803 46657569
Gastrooesophageal reflux disease 17.19 15.75 5 19685 74339 46592033
Chest pain 17.18 15.75 30 19660 176294 46490078
Hypersensitivity 17.12 15.75 23 19667 150298 46516074
Dyspepsia 16.99 15.75 4 19686 68468 46597904
Cytomegalovirus test positive 16.93 15.75 12 19678 2808 46663564
Sinusitis 16.75 15.75 18 19672 129750 46536622
Stem cell transplant 16.72 15.75 10 19680 1756 46664616
Drug ineffective for unapproved indication 16.68 15.75 27 19663 16386 46649986
Differentiation syndrome 16.67 15.75 8 19682 903 46665469
Neutrophil count decreased 16.58 15.75 48 19642 43378 46622994
Extraskeletal ossification 16.48 15.75 4 19686 53 46666319
Abscess fungal 16.15 15.75 4 19686 58 46666314
Anal infection 16.08 15.75 4 19686 59 46666313
Shock haemorrhagic 16.05 15.75 19 19671 8605 46657767
Weight increased 16.01 15.75 28 19662 164445 46501927
Acinetobacter infection 15.98 15.75 9 19681 1413 46664959
Respiratory distress 15.97 15.75 39 19651 31877 46634495
Cytopenia 15.95 15.75 18 19672 7750 46658622
Liver sarcoidosis 15.92 15.75 3 19687 10 46666362
Sunburn 15.80 15.75 11 19679 2501 46663871

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bronchopulmonary aspergillosis 764.03 14.16 336 32088 11948 29908106
Aspergillus infection 712.51 14.16 303 32121 9911 29910143
Photosensitivity reaction 621.65 14.16 271 32153 9423 29910631
Drug interaction 437.21 14.16 776 31648 198792 29721262
Drug level increased 401.23 14.16 249 32175 18105 29901949
Periostitis 329.52 14.16 72 32352 181 29919873
Mucormycosis 314.08 14.16 140 32284 5128 29914926
Fungal infection 308.59 14.16 189 32235 13411 29906643
Cerebral aspergillosis 294.30 14.16 93 32331 1265 29918789
Actinic keratosis 251.42 14.16 107 32317 3496 29916558
Drug ineffective 226.67 14.16 843 31581 339544 29580510
Scedosporium infection 214.99 14.16 63 32361 652 29919402
Drug resistance 211.71 14.16 175 32249 19958 29900096
Multiple organ dysfunction syndrome 197.01 14.16 290 32134 63197 29856857
Hallucination, visual 192.63 14.16 151 32273 15962 29904092
Squamous cell carcinoma of skin 158.27 14.16 107 32317 8988 29911066
Hallucination 154.87 14.16 226 32198 48833 29871221
Graft versus host disease 152.25 14.16 109 32315 10041 29910013
Squamous cell carcinoma 142.21 14.16 105 32319 10145 29909909
Photodermatosis 138.18 14.16 40 32384 395 29919659
Hepatotoxicity 137.41 14.16 131 32293 18014 29902040
Fatigue 133.98 14.16 92 32332 320581 29599473
Pneumonia fungal 130.85 14.16 79 32345 5454 29914600
Respiratory failure 127.98 14.16 314 32110 100328 29819726
Condition aggravated 126.16 14.16 381 32043 137485 29782569
Septic shock 125.24 14.16 237 32187 63370 29856684
Pathogen resistance 120.84 14.16 88 32336 8322 29911732
Febrile neutropenia 105.28 14.16 303 32121 106390 29813664
Cholestasis 98.32 14.16 128 32296 24822 29895232
Completed suicide 94.13 14.16 3 32421 99489 29820565
Systemic mycosis 91.12 14.16 38 32386 1178 29918876
Choroiditis 90.25 14.16 34 32390 801 29919253
Hepatic function abnormal 89.67 14.16 162 32262 41783 29878271
Drug level below therapeutic 86.89 14.16 51 32373 3341 29916713
Visual impairment 85.69 14.16 133 32291 30305 29889749
Fluoride increased 84.55 14.16 18 32406 38 29920016
Myocardial infarction 83.86 14.16 17 32407 125608 29794446
Cheilitis 82.81 14.16 43 32381 2213 29917841
Solar lentigo 80.84 14.16 25 32399 315 29919739
Endophthalmitis 80.51 14.16 49 32375 3431 29916623
Fall 73.34 14.16 54 32370 181818 29738236
Drug level decreased 72.81 14.16 56 32368 5749 29914305
Drug abuse 72.55 14.16 4 32420 82068 29837986
Fungaemia 71.93 14.16 39 32385 2192 29917862
Fusarium infection 68.96 14.16 30 32394 1034 29919020
Dysplastic naevus 67.13 14.16 22 32402 338 29919716
Phaeohyphomycosis 66.17 14.16 27 32397 791 29919263
Candida infection 65.53 14.16 82 32342 15280 29904774
Immunosuppressant drug level increased 64.83 14.16 48 32376 4654 29915400
Drug level above therapeutic 64.46 14.16 40 32384 2899 29917155
Acute myeloid leukaemia 64.21 14.16 88 32336 17918 29902136
Product dose omission issue 64.12 14.16 11 32413 91620 29828434
Mycotic endophthalmitis 62.25 14.16 14 32410 42 29920012
Pain 61.28 14.16 58 32366 172583 29747471
Graft versus host disease in gastrointestinal tract 60.40 14.16 39 32385 3030 29917024
Aspergilloma 60.34 14.16 20 32404 319 29919735
Fluorosis 55.32 14.16 13 32411 50 29920004
Asthenia 55.17 14.16 97 32327 221193 29698861
Nephropathy toxic 53.92 14.16 62 32362 10577 29909477
Acute myeloid leukaemia recurrent 52.47 14.16 28 32396 1524 29918530
Product use in unapproved indication 52.26 14.16 187 32237 73506 29846548
Dyspnoea 52.04 14.16 186 32238 333109 29586945
Inappropriate antidiuretic hormone secretion 51.99 14.16 63 32361 11359 29908695
Treatment failure 50.26 14.16 114 32310 34565 29885489
Depression 49.51 14.16 18 32406 90419 29829635
Hepatocellular injury 47.71 14.16 93 32331 25378 29894676
Trichosporon infection 47.57 14.16 20 32404 633 29919421
Disseminated mucormycosis 47.41 14.16 14 32410 149 29919905
Dyschromatopsia 46.84 14.16 16 32408 281 29919773
Pseudomonas infection 46.38 14.16 57 32367 10425 29909629
Nausea 46.13 14.16 166 32258 296791 29623263
Anxiety 45.74 14.16 20 32404 89851 29830203
Brain abscess 45.34 14.16 31 32393 2650 29917404
Neurological symptom 44.87 14.16 34 32390 3413 29916641
Neurotoxicity 44.86 14.16 63 32361 13119 29906935
Chest pain 44.73 14.16 37 32387 117590 29802464
Dizziness 44.54 14.16 90 32334 194819 29725235
Diarrhoea 44.20 14.16 199 32225 333904 29586150
Liver disorder 43.39 14.16 98 32326 29624 29890430
Disseminated intravascular coagulation 42.80 14.16 82 32342 22089 29897965
Cardiac failure congestive 42.61 14.16 19 32405 84388 29835666
Constipation 42.33 14.16 36 32388 112870 29807184
Product compounding quality issue 41.65 14.16 9 32415 21 29920033
Leukaemia recurrent 41.38 14.16 24 32400 1537 29918517
Cytokine release syndrome 40.74 14.16 52 32372 9881 29910173
Renal ischaemia 40.73 14.16 17 32407 528 29919526
Central nervous system fungal infection 40.51 14.16 14 32410 255 29919799
Uveitis 40.41 14.16 39 32385 5438 29914616
Pruritus 40.41 14.16 41 32383 118163 29801891
Pain in extremity 40.29 14.16 36 32388 110185 29809869
Geotrichum infection 39.36 14.16 16 32408 464 29919590
Alternaria infection 38.27 14.16 14 32410 303 29919751
Visual acuity reduced 37.46 14.16 64 32360 15782 29904272
Cytomegalovirus viraemia 37.10 14.16 38 32386 5691 29914363
Arthralgia 37.08 14.16 56 32368 135735 29784319
Intraocular pressure increased 36.92 14.16 36 32388 5084 29914970
Enterococcal infection 36.84 14.16 45 32379 8179 29911875
Dehydration 36.66 14.16 48 32376 123491 29796563
Burns second degree 36.20 14.16 14 32410 355 29919699
Enterococcal sepsis 36.07 14.16 22 32402 1546 29918508
Graft versus host disease in skin 35.26 14.16 29 32395 3278 29916776
Acute graft versus host disease in liver 35.17 14.16 20 32404 1234 29918820
Hepatitis cholestatic 35.14 14.16 43 32381 7829 29912225
Blood pressure increased 35.05 14.16 17 32407 71911 29848143
Aspergillus test positive 34.57 14.16 14 32410 402 29919652
Product contamination microbial 34.41 14.16 16 32408 646 29919408
Nocardiosis 34.15 14.16 29 32395 3426 29916628
Drug ineffective for unapproved indication 34.09 14.16 50 32374 10830 29909224
Eye infection fungal 34.09 14.16 13 32411 317 29919737
Rheumatoid arthritis 33.53 14.16 3 32421 41194 29878860
Blood alkaline phosphatase increased 33.49 14.16 92 32332 31395 29888659
Acute graft versus host disease in skin 33.02 14.16 32 32392 4484 29915570
Pneumonia 33.01 14.16 526 31898 333780 29586274
Photophobia 32.98 14.16 36 32388 5800 29914254
Scopulariopsis infection 32.93 14.16 10 32414 118 29919936
Peripheral swelling 32.01 14.16 13 32411 61061 29858993
Acute respiratory distress syndrome 31.63 14.16 75 32349 23397 29896657
Septic embolus 31.55 14.16 18 32406 1117 29918937
Cystitis haemorrhagic 31.45 14.16 32 32392 4755 29915299
Intentional overdose 31.26 14.16 4 32420 41477 29878577
Post transplant lymphoproliferative disorder 30.45 14.16 33 32391 5273 29914781
Vomiting 30.16 14.16 129 32295 219689 29700365
Nasopharyngitis 30.08 14.16 13 32411 58836 29861218
Pulmonary cavitation 30.02 14.16 15 32409 711 29919343
Cerebrovascular accident 29.62 14.16 28 32396 83449 29836605
Hyperhidrosis 29.56 14.16 18 32406 67072 29852982
Hypertension 29.45 14.16 54 32370 121300 29798754
Acute graft versus host disease 29.42 14.16 34 32390 5830 29914224
Pseudoporphyria 29.28 14.16 11 32413 257 29919797
Cytomegalovirus infection 29.08 14.16 73 32351 23601 29896453
Hepatic failure 29.07 14.16 92 32332 33951 29886103
Central nervous system lesion 29.01 14.16 31 32393 4875 29915179
Weight decreased 28.57 14.16 77 32347 150844 29769210
Torsade de pointes 28.48 14.16 37 32387 7153 29912901
Acute myocardial infarction 28.19 14.16 11 32413 52928 29867126
Malaise 28.11 14.16 90 32334 166872 29753182
Toxic optic neuropathy 27.94 14.16 14 32410 668 29919386
Urinary bladder rupture 27.82 14.16 7 32417 38 29920016
Lip squamous cell carcinoma 27.63 14.16 8 32416 79 29919975
Drug-induced liver injury 27.61 14.16 67 32357 21207 29898847
Back pain 27.33 14.16 43 32381 102553 29817501
Lentigo 27.16 14.16 11 32413 316 29919738
Transmission of an infectious agent via product 26.30 14.16 9 32415 159 29919895
Xanthopsia 26.25 14.16 9 32415 160 29919894
Headache 26.23 14.16 105 32319 182201 29737853
Photopsia 26.17 14.16 19 32405 1787 29918267
Pyrexia 25.95 14.16 455 31969 294034 29626020
Gallbladder empyema 25.94 14.16 7 32417 52 29920002
Acanthamoeba keratitis 25.92 14.16 8 32416 100 29919954
Neutropenia 25.88 14.16 232 32192 128308 29791746
Sepsis 25.88 14.16 257 32167 146138 29773916
Psoriasis 25.86 14.16 7 32417 42499 29877555
Urinary tract infection 25.79 14.16 25 32399 73634 29846420
Disease recurrence 25.65 14.16 51 32373 14110 29905944
Fungal skin infection 25.25 14.16 21 32403 2411 29917643
Muscle spasms 25.12 14.16 20 32404 64818 29855236
Gallbladder oedema 24.85 14.16 9 32415 189 29919865
Tongue necrosis 24.78 14.16 6 32418 27 29920027
Gamma-glutamyltransferase increased 24.77 14.16 79 32345 29271 29890783
Nervous system disorder 23.59 14.16 47 32377 13022 29907032
Chromatopsia 23.43 14.16 9 32415 224 29919830
Arthritis fungal 23.42 14.16 7 32417 78 29919976
Inappropriate schedule of product administration 23.32 14.16 7 32417 39721 29880333
Eye pain 23.24 14.16 44 32380 11745 29908309
Pulmonary alveolar haemorrhage 23.21 14.16 32 32392 6549 29913505
Dyspnoea exertional 23.18 14.16 5 32419 35425 29884629
BK virus infection 23.07 14.16 26 32398 4338 29915716
Hypertrophic osteoarthropathy 23.02 14.16 7 32417 83 29919971
Rectal haemorrhage 22.72 14.16 5 32419 34934 29885120
Dyspepsia 22.67 14.16 3 32421 30326 29889728
Abscess fungal 22.64 14.16 8 32416 156 29919898
Chronic graft versus host disease 22.57 14.16 25 32399 4094 29915960
Retinal ischaemia 22.53 14.16 10 32414 362 29919692
Pulmonary embolism 22.51 14.16 31 32393 78104 29841950
Cytomegalovirus enterocolitis 22.49 14.16 13 32411 827 29919227
Pulmonary haemorrhage 22.28 14.16 38 32386 9354 29910700
Gastrooesophageal reflux disease 22.27 14.16 4 32420 32251 29887803
Urticaria 22.23 14.16 16 32408 54590 29865464
Fungal endocarditis 22.14 14.16 8 32416 167 29919887
Klebsiella infection 22.08 14.16 32 32392 6855 29913199
Infectious pleural effusion 22.06 14.16 18 32406 2012 29918042
Asthma 21.92 14.16 6 32418 36168 29883886
Necrotising retinitis 21.51 14.16 12 32412 713 29919341
Acute graft versus host disease in intestine 21.37 14.16 19 32405 2386 29917668
Lung infiltration 21.29 14.16 44 32380 12515 29907539
Ureaplasma infection 21.21 14.16 8 32416 189 29919865
Systemic candida 20.99 14.16 20 32404 2744 29917310
Altered state of consciousness 20.97 14.16 58 32366 19861 29900193
Pulmonary mucormycosis 20.94 14.16 10 32414 429 29919625
Lower respiratory tract infection fungal 20.93 14.16 11 32413 580 29919474
Cerebral fungal infection 20.90 14.16 8 32416 197 29919857
Sunburn 20.82 14.16 16 32408 1640 29918414
Pulmonary mass 20.74 14.16 40 32384 10822 29909232
Osteomyelitis fungal 20.68 14.16 8 32416 203 29919851
Pancytopenia 20.56 14.16 160 32264 84892 29835162
Burns first degree 20.55 14.16 4 32420 4 29920050
Peptic ulcer haemorrhage 20.19 14.16 10 32414 465 29919589
Scintillating scotoma 20.05 14.16 5 32419 26 29920028
Organising pneumonia 19.92 14.16 26 32398 5048 29915006
Neurological decompensation 19.91 14.16 18 32406 2310 29917744
Meningitis coccidioides 19.90 14.16 5 32419 27 29920027
Musculoskeletal stiffness 19.86 14.16 7 32417 35874 29884180
Leukaemia 19.79 14.16 21 32403 3276 29916778
Angina pectoris 19.65 14.16 4 32420 29514 29890540
Citrobacter infection 19.36 14.16 10 32414 509 29919545
Colour blindness acquired 19.30 14.16 6 32418 77 29919977
Eye abscess 19.11 14.16 7 32417 152 29919902
Bacterial sepsis 18.97 14.16 25 32399 4901 29915153
Splenic candidiasis 18.69 14.16 6 32418 86 29919968
Syncope 18.67 14.16 40 32384 84863 29835191
Halo vision 18.46 14.16 7 32417 168 29919886
Hyperammonaemia 18.21 14.16 26 32398 5494 29914560
Retinal haemorrhage 18.15 14.16 24 32400 4719 29915335
International normalised ratio increased 18.14 14.16 15 32409 47724 29872330
Fibrinous bronchitis 18.04 14.16 4 32420 11 29920043
Transaminases increased 17.87 14.16 61 32363 23396 29896658
Oral papilloma 17.79 14.16 4 32420 12 29920042
Neuroendocrine carcinoma of the skin 17.76 14.16 10 32414 605 29919449
Abdominal pain 17.72 14.16 81 32343 135573 29784481
Transplant rejection 17.70 14.16 34 32390 9172 29910882
Macular opacity 17.49 14.16 3 32421 0 29920054
Inhibitory drug interaction 17.24 14.16 14 32410 1554 29918500
Intentional product misuse 17.18 14.16 8 32416 34659 29885395
Drug hypersensitivity 17.05 14.16 30 32394 68489 29851565
Decreased appetite 17.03 14.16 94 32330 149816 29770238
Disease progression 17.01 14.16 146 32278 79728 29840326
Hypoxia 16.96 14.16 99 32325 47755 29872299
Chronic obstructive pulmonary disease 16.91 14.16 15 32409 46111 29873943
Gastrointestinal wall thinning 16.90 14.16 4 32420 16 29920038
Abdominal pain upper 16.85 14.16 26 32398 62525 29857529
Thrombotic microangiopathy 16.80 14.16 32 32392 8578 29911476
Hospitalisation 16.75 14.16 14 32410 44305 29875749
Gait disturbance 16.63 14.16 35 32389 74742 29845312
Aspartate aminotransferase 16.57 14.16 6 32418 126 29919928
Granulomatous dermatitis 16.55 14.16 7 32417 225 29919829
Blood bilirubin increased 16.53 14.16 81 32343 36555 29883499
Prostate cancer 16.47 14.16 3 32421 23954 29896100
Joint swelling 16.35 14.16 16 32408 46930 29873124
Acute lymphocytic leukaemia recurrent 16.03 14.16 17 32407 2650 29917404
Apraxia 15.96 14.16 12 32412 1190 29918864
Overdose 15.96 14.16 43 32381 84294 29835760
Flushing 15.91 14.16 6 32418 29486 29890568
Solar dermatitis 15.75 14.16 5 32419 69 29919985
Toxic skin eruption 15.71 14.16 36 32388 10979 29909075
Chronic granulomatous disease 15.71 14.16 4 32420 23 29920031
Periostosis 15.71 14.16 4 32420 23 29920031
Sinusitis fungal 15.67 14.16 8 32416 397 29919657
Bacterial infection 15.60 14.16 39 32385 12571 29907483
Hepatitis toxic 15.60 14.16 15 32409 2082 29917972
Chondritis 15.55 14.16 6 32418 151 29919903
Candida test positive 15.52 14.16 8 32416 405 29919649
Ephelides 15.49 14.16 5 32419 73 29919981
Chronic pulmonary histoplasmosis 15.41 14.16 3 32421 3 29920051
Lip ulceration 15.41 14.16 10 32414 783 29919271
Pneumonia cytomegaloviral 15.37 14.16 17 32407 2779 29917275
Nephrolithiasis 15.25 14.16 4 32420 24806 29895248
Hallucinations, mixed 15.23 14.16 16 32408 2467 29917587
Drug reaction with eosinophilia and systemic symptoms 15.03 14.16 6 32418 28482 29891572
Keratitis fungal 15.01 14.16 5 32419 81 29919973
Hypersensitivity 15.00 14.16 22 32402 54006 29866048
Escherichia sepsis 14.96 14.16 20 32404 3974 29916080
Product use issue 14.90 14.16 93 32331 45923 29874131
Arthritis 14.87 14.16 4 32420 24397 29895657
Pneumonia bacterial 14.84 14.16 32 32392 9371 29910683
Aplasia 14.79 14.16 20 32404 4017 29916037
Hypokalaemia 14.76 14.16 99 32325 50093 29869961
Mental disorder due to a general medical condition 14.73 14.16 6 32418 175 29919879
Venoocclusive liver disease 14.70 14.16 26 32398 6587 29913467
Staphylococcal sepsis 14.64 14.16 32 32392 9459 29910595
Loss of consciousness 14.62 14.16 41 32383 79334 29840720
Deep vein thrombosis 14.59 14.16 27 32397 60474 29859580
Necrotising ulcerative gingivostomatitis 14.58 14.16 5 32419 89 29919965
Blood beta-D-glucan increased 14.44 14.16 8 32416 469 29919585
Brain herniation 14.43 14.16 19 32405 3721 29916333
Abdominal discomfort 14.41 14.16 19 32405 48772 29871282
Injury 14.35 14.16 3 32421 21728 29898326
Off label use 14.33 14.16 362 32062 248928 29671126
Disseminated aspergillosis 14.32 14.16 5 32419 94 29919960
Penicillium infection 14.32 14.16 5 32419 94 29919960

Pharmacologic Action:

SourceCodeDescription
ATC J02AC03 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
Triazole derivatives
FDA CS M0002083 Azoles
MeSH PA D058888 14-alpha Demethylase Inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000935 Antifungal Agents
MeSH PA D065692 Cytochrome P-450 CYP3A Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006727 Hormone Antagonists
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D065088 Steroid Synthesis Inhibitors
FDA EPC N0000175487 Azole Antifungal
CHEBI has role CHEBI:50183 cytochrome p450 inhibitor
FDA MoA N0000182140 Cytochrome P450 2C19 Inhibitors
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000185504 Cytochrome P450 2C9 Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Invasive pulmonary aspergillosis indication 3214003
Candidiasis of the esophagus indication 20639004 DOID:13146
Fusarium infection indication 64250002
Disseminated candidiasis indication 70572005
Candidemia indication 432261003
Fungal Infection due to Scedosporium Apiospermum indication
Fungal Infection due to Fusarium Solani indication
Oropharyngeal Candidiasis off-label use
Hypocalcemia contraindication 5291005
Torsades de pointes contraindication 31722008
Hypokalemia contraindication 43339004
Cardiomyopathy contraindication 85898001 DOID:0050700
Prolonged QT interval contraindication 111975006
Hypomagnesemia contraindication 190855004
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Poor metabolizer due to cytochrome p450 CYP2C19 variant contraindication 424500005
Congenital long QT syndrome contraindication 442917000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.93 acidic
pKa2 2.85 Basic
pKa3 1.42 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
200MG VFEND PF PRISM CV N021266 May 24, 2002 RX TABLET ORAL Jan. 29, 2022 NEW PATIENT POPULATION
50MG VFEND PF PRISM CV N021266 May 24, 2002 RX TABLET ORAL Jan. 29, 2022 NEW PATIENT POPULATION
200MG/VIAL VFEND PF PRISM CV N021267 May 24, 2002 RX INJECTABLE INTRAVENOUS Jan. 29, 2022 NEW PATIENT POPULATION
200MG/5ML VFEND PF PRISM CV N021630 Dec. 19, 2003 RX FOR SUSPENSION ORAL Jan. 29, 2022 NEW PATIENT POPULATION

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cytochrome P450 3A4 Enzyme IC50 4.89 CHEMBL
Cytochrome P450 2C9 Enzyme IC50 4.85 CHEMBL
Cytochrome P450 2C19 Enzyme IC50 4.82 CHEMBL
Lanosterol 14-alpha demethylase Enzyme INHIBITOR MIC 8.73 WOMBAT-PK CHEMBL
Lanosterol 14-alpha demethylase Enzyme MIC 5.84 WOMBAT-PK
14-alpha sterol demethylase Enzyme Kd 6.37 CHEMBL
14-alpha sterol demethylase Cyp51A Enzyme Kd 5.44 CHEMBL

External reference:

IDSource
4021347 VUID
N0000148767 NUI
D00578 KEGG_DRUG
4021347 VANDF
C0532517 UMLSCUI
CHEBI:10023 CHEBI
VOR PDB_CHEM_ID
CHEMBL638 ChEMBL_ID
D065819 MESH_DESCRIPTOR_UI
7269 INN_ID
JFU09I87TR UNII
71616 PUBCHEM_CID
DB00582 DRUGBANK_ID
121243 RXNORM
16711 MMSL
179944 MMSL
43734 MMSL
d04803 MMSL
009650 NDDF
385469007 SNOMEDCT_US
386116008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
VFEND HUMAN PRESCRIPTION DRUG LABEL 1 0049-3160 POWDER, FOR SUSPENSION 40 mg ORAL NDA 34 sections
VFEND HUMAN PRESCRIPTION DRUG LABEL 1 0049-3170 TABLET, FILM COATED 50 mg ORAL NDA 34 sections
VFEND HUMAN PRESCRIPTION DRUG LABEL 1 0049-3180 TABLET, FILM COATED 200 mg ORAL NDA 34 sections
VFEND HUMAN PRESCRIPTION DRUG LABEL 1 0049-3190 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 34 sections
VFEND HUMAN PRESCRIPTION DRUG LABEL 1 0049-3190 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 34 sections
VFEND HUMAN PRESCRIPTION DRUG LABEL 1 0049-3190 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 34 sections
VFEND HUMAN PRESCRIPTION DRUG LABEL 1 0049-4190 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 33 sections
Voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 0378-1626 TABLET, FILM COATED 50 mg ORAL ANDA 31 sections
Voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 0378-1640 TABLET, FILM COATED 200 mg ORAL ANDA 31 sections
Voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 0781-3416 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS ANDA 30 sections
voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 0781-5667 TABLET, FILM COATED 50 mg ORAL ANDA 30 sections
voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 0781-5668 TABLET, FILM COATED 200 mg ORAL ANDA 30 sections
voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6471 TABLET, FILM COATED 200 mg ORAL ANDA 30 sections
voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6596 TABLET 50 mg ORAL ANDA 28 sections
Voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-7024 TABLET 200 mg ORAL ANDA 27 sections
Voriconazole Human Prescription Drug Label 1 27241-062 TABLET 50 mg ORAL ANDA 27 sections
Voriconazole Human Prescription Drug Label 1 27241-063 TABLET 200 mg ORAL ANDA 27 sections
Voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 39822-1077 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 29 sections
voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 40032-038 SUSPENSION 40 mg ORAL ANDA 29 sections
voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 40032-088 TABLET, FILM COATED 50 mg ORAL ANDA 28 sections
voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 40032-089 TABLET, FILM COATED 200 mg ORAL ANDA 28 sections
VORICONULLZOLE HUMAN PRESCRIPTION DRUG LABEL 1 43386-038 POWDER, FOR SUSPENSION 40 mg ORAL ANDA 29 sections
voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 43386-088 TABLET, FILM COATED 50 mg ORAL ANDA 29 sections
voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 43386-089 TABLET, FILM COATED 200 mg ORAL ANDA 29 sections
Voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 43547-377 TABLET, COATED 50 mg ORAL ANDA 18 sections
Voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 43547-378 TABLET, COATED 200 mg ORAL ANDA 18 sections
VORICONULLZOLE HUMAN PRESCRIPTION DRUG LABEL 1 47781-466 INJECTION, POWDER, FOR SOLUTION 10 mg INTRAVENOUS ANDA 27 sections
Voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 51079-164 TABLET, FILM COATED 50 mg ORAL ANDA 31 sections
Voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 51079-165 TABLET, FILM COATED 200 mg ORAL ANDA 31 sections
voriconazole HUMAN PRESCRIPTION DRUG LABEL 1 51407-133 TABLET, FILM COATED 200 mg ORAL ANDA 28 sections